PetCaseFinder

Peer-reviewed veterinary case report

T-lymphocyte levels linked to benign and malignant dog mammary tumors

By Carvalho, Maria Isabel et al.·Published in In vivo (Athens, Greece)·2011·Department of Veterinary Sciences·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: T-lymphocytic infiltrate in canine mammary tumours: clinic and prognostic implications.

Species:
dog

Plain-English summary

A study looked at 57 dogs with mammary tumors, both benign and malignant, to see how certain immune cells (T-lymphocytes) affected their health. It found that benign tumors had more of these immune cells compared to malignant ones, which had higher levels of immune cells around the tumor. Interestingly, dogs with more immune cells in the surrounding healthy tissue tended to have a shorter survival time. This suggests that the presence of these immune cells might be linked to how aggressive the tumor is, but more research is needed to understand this better.

People also search for: dog mammary tumor prognosis · canine mammary tumor treatment · immune system and dog cancer · T-lymphocytes in dog tumors

Abstract

In recent years, considerable progress has been made in understanding the role of the immune system in tumour progression. However, in canine mammary tumours (CMT), the prognostic value of T-lymphocytes is not established. The aims of the present study were to characterize T-lymphocytic infiltrate in 57 canine mammary tumours (21 benign and 36 malign), by immunohistochemical detection of CD3 antigen, and to determine its association with several clinicopathological parameters and overall survival. CD3+ positive cells were counted in 10 high-power fields within the tumour (i.e. The tumour-infiltrating T-lymphocytes, TIL), in the peripheral area of the tumour and in the adnexal non-tumoural mammary gland. CD3(+) TILs were significantly more frequent in benign than in malignant tumours (p<0.001). Conversely, peripheral CD3(+) TILs were significantly more frequent in malignant than in benign neoplasias (p<0.001). For CD3(+) T-lymphocytes in the adnexal non-tumoural mammary gland, there was no statistical difference in their frequency between benign and malignant tumours. On survival analysis, there was a tendency towards an association of a higher number of CD3(+) TILs and a shorter overall survival (p=0.08). Interestingly for CD3(+) T-lymphocytes in the adnexal non-tumoural mammary gland, a statistically significant relationship was observed, with a higher number of lymphocytes conferring a reduced overall survival (p=0.045). Further studies will be required to better understand the biological implications of the current findings.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/22021690/